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Background: To compare pain response outcomes for patients with spinal bone metastases treated with resistance
training of the spinal musculature versus passive physical therapy during radiotherapy (RT).
Methods: In this randomized trial, 60 consecutive patients were treated from September 2011 until March 2013
within one of the two groups: resistance training (Arm A) or passive physical therapy (Arm B) with thirty patients in
each group during RT. The course of pain according to visual analog scale (VAS), concurrent medication, and oral
morphine equivalent dose (OMED) were assessed at baseline, three months, and six months after RT. Pain response
was determined using International Bone Consensus response definitions.
Results: The course of VAS in the intervention group (Arm A) was significantly lower both during and after RT
(AUC, p < .001). The use of analgetic medication showed the same result, with significantly fewer analgetics being
necessary both during and after RT in arm A (p < .001). In the course of time, the OMED decreased in arm A, but
increased in arm B. After 6 month, 72.2% of patients in arm A, and 22.2% in arm B were responders (p = .014).
Conclusion: Our trial demonstrated that guided isometric resistance training of the paravertebral muscles can
improve pain relief over a 6-months period in patients with stable spinal metastases. Importantly, the intervention
was able to reduce OMED as well as concomitant pain medication. The trial is registered in Clinical trial identifier
NCT 01409720 (http://www.clinicaltrials.gov/) since 2nd of August 2011.
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radiotherapyBackground
The spine is the most common site of bone metastases
[1,2]. Bone metastases are a major clinical concern and
cause severe pain, pathological fractures, spinal cord
compression, hypercalcaemia with a significant decrease
in quality of life [3]. Pain remains the most frequent
symptom and the most important factor impairing the
mobility and quality of life in patients with bone metas-
tases [4]. Radiotherapy (RT) is a well-established non-* Correspondence: harald.rief@med.uni-heidelberg.de
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unless otherwise stated.pharmacological effective treatment for the alleviation of
pain from spinal metastases [5,6]. Other therapeutic op-
tions used to treat pain in addition to RT involve anal-
getics, systemic therapy, bisphosphonates, and minimal
invasive surgery [3]. For these reasons, pain relief is an
important clinical challenge and represents the primary
goal of any therapy aiming to manage bone metastases
[7]. Due to the potentially raised risk of pathological
fractures, physicians have so far refrained from initiating
forms of intervention involving sport exercises in pa-
tients with bone metastases, and there are no specifically
exercise-related therapeutic measures involving iso-
metric muscle training described in the literature in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tients of any primary, there are numerous indications of
the positive effect of targeted resistance training mea-
sures regarding pain and mobility [4,8,9]. Accordingly
the effect of muscle-training exercises as an adjunct to
RT in patients with bone metastases is still unknown.
The underlying concept of this randomized study is to
compare the pain response of an isometric resistance
training regimen of the paravertebral muscles as an ad-
junct to RT vs. RT alone in patients with spinal bone
metastases. The objective may be seen as the integration
of a combination therapy in palliative-care patients to




From September 2011 until March 2013, 80 consecutive
patients with a histologically confirmed cancer of any
primary and solitary or multiple bone metastases of the
thoracic or lumbar segments of the vertebral column or
of the os sacrum were screened in the Radiooncology
Department of the Heidelberg University Clinic. Initially
all patients were diagnosed as having painful bone me-
tastases requiring RT. Inclusion criteria were an age of
18 to 80 years, a Karnofsky performance score [10] ≥ 70,Figure 1 Flow of participants through the trial.written consent to participate, and already initiated bis-
phosphonate therapy. The patients were subjected to a
staging of their vertebral column within the context of
the CT designed to plan the radiation schedule prior to
enrolment into the trial. In this examination metastases
in the thoracic and lumbar spine were classified as
“stable” or “unstable”. Patients with stable vertebral-body
lesions were included. Out of 80 patients considered eli-
gible, 15 patients were excluded due to unstable me-
tastases, and five patients declined to participate in the
study. 60 patients fulfilled the inclusion and were en-
rolled into the trial (Figure 1). The study was approved
by the Heidelberg Ethics Committee (Nr. S-316/2011).
Design, randomized allocation, and procedures
This is a randomized, controlled, explorative intervention
trial to compare pain response of a resistance training pro-
gram for strengthening the paravertebral muscles in pa-
tients with bone metastases as an adjunct to RT. Patients
in the control group conducted passive physical therapy in
the form of respiratory exercises. A block randomization
approach with block size 6 was used to ensure that the
two groups were balanced. After baseline measurements,
the patients with stable bone metastases were assigned to
the respective treatment arms on a 1:1 basis according to
the randomization list. The randomization procedure was
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resistance training) and in Arm B (control group, passive
physical therapy) each consisted of 30 patients. The target
parameters were measured at the start of radiotherapy (t0),
end of RT (t1), after twelve weeks (t2), and after six month
(t3). The target parameters comprise the documentation of
visual analog scale (VAS), neuropathic pain, oral morphine
equivalent dose (OMED), concurrent medication, and theTable 1 Patient characteristics at baseline
Intervention
n
Age (years) Mean (SD) 61.3 (10.1)
Gender Male 14
Female 16











Thoracic and lumbar 2
Sacrum 2
Number metastases


















Abbreviation: SD standard deviation.recording of patient-specific data. VAS and concurrent
medication were documented daily for twelve weeks, and
once after 6 month. VAS values following RT were re-
corded as the mean value for the week. In addition, the
basic pain medication and concomitant medication from
the start of RT until twelve weeks after RT were recorded
daily and also six months after RT. During the therapy the
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Figure 2 Visual analog scale during and after RT. a. VAS course
during intervention and RT (T0-T1). b. VAS course after intervention
and RT (T1-T2).
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the form of a pain diary. Neuropathic pain was also re-
corded. The opioid analgetics were converted into an oral
morphine equivalent dose (OMED). Non-opioid analgetics
were also recorded. The data of the patient records were
collected by the authors. Patient characteristics are shown
in Table 1.
Study interventions
The interventions commenced on the same day as RT and
were performed on each day of RT treatment (Monday
through Friday) over a two-week period, independent of
the number of fractions. During the two-week RT period,
the patients in the resistance training group (Arm A) per-
formed the exercises under guidance of a physiotherapist.
The patients were then instructed to practice the training
in their homes three times a week and continued the re-
sistance training themselves until the last investigation after
six months. The resistance training lasted approx. 30 min,
the physical therapy (Arm B) approx. 15 min. Since the site
of the bone metastases differed from patient to patient,
three different exercises were enacted to ensure an even
isometric resistance training of the muscles along the entire
vertebral column. The patients of the control group re-
ceived physical therapy in the form of respiratory exercises
also for a period of two weeks. A detailed report of
the intervention and its application has already been
published [11].
Measures of the endpoint
The endpoint was pain response, defined according to
the International Bone Consensus response categories by
Chow et al. [12] as complete response (CR), partial re-
sponse (PR), pain progression (PP), and stable pain (SP) at
three and six months after RT. The pain was documented
on the visual analog scale (range 0–100). Complete re-
sponse was defined as VAS = 0 at treated site with no con-
comitant increase in analgetic intake (stable or reducing
analgetics in daily oral morphine equivalent dose). Partial
response was defined as pain reduction of 2 or more at
the treated site without analgetic increase, or analgetic re-
duction of 25% or more from baseline without an increase
in pain. Pain progression was defined as increase in pain
score of 2 or more above baseline at the treated site with
stable OMED, or an increase of 25% or more in OMED
compared with baseline with the pain score stable or 1
point above baseline. Any response not covered by the
complete response, partial response, or pain progression
definitions was called “stable pain” [13]. Responders were
defined as CR + PR, non-responders as PP + SP.
Radiotherapy
RT was performed in the Radiooncology Department of
the Heidelberg University Clinic. After virtual simulationwas performed to plan the radiation schedule, RT was car-
ried out over a dorsal photon field of the 6MV energy
range. PTV covered the specific vertebral body affected as
well as the ones immediately above and below. In Arm A
24 patients (80%) were treated with 10 × 3 Gy, three pa-
tients (10%) with 14 × 2.5 Gy, and three patients (10%)
with 20 × 2 Gy. In Arm B the dose fractions for 28
patients (93.3%) were 10 × 3 Gy, for one patient (3.3%)
14 × 2.5 Gy, and for one patient (3.3%) 20 × 2 Gy. The
median individual dose in all patients was 3 Gy (range
2–3 Gy), the median total dose 30 Gy (range 20–35 Gy).
The individual and total doses were decided separately for
each individual patient, depending on the histology, the
patient’s general state of health, and on the current staging
and the corresponding prognosis.
Sample calculation and statistical analysis
The total number of patients undergoing RT in the radia-
tion oncology department of the Heidelberg University
Clinic for metastatic processes in the vertebral column in
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shall fulfill the inclusion criteria. On account of the
explorative character of this study, it was not possible to
estimate the total number of cases; with a scheduled num-
ber of 30 patients per group, it will, however, be possible
to detect a standardized mean-value effect of 0.8 with a
power of 80% and an significance level of 5%. All variables
were analyzed descriptively by tabulation of the measures
of the empirical distributions. According to the scale level
of the variables, means and standard deviations or abso-
lute and relative frequencies, respectively, were reported.
Additionally, for variables with longitudinal measure-
ments, the time courses of individual patients and sum-
marized by treatment groups. Descriptive p-values of the
corresponding statistical tests comparing the treatment
groups will be given. The VAS was adjusted for concurrent
medication. Analysis of covariance (ANOVA) with repeated
measurements, with group as factor, time (days during RT,
weeks after RT), and pain medications as covariance were
done. Area under the curve was divided by number of
visits per patient. Wilcoxon test was used to detect pos-
sible differences between groups. Graphical visualization
includes boxplots and means course over time.
Results
The mean follow-up was 6.3 months for both groups.
During the trial there were no adverse events. All survi-
ving patients completed all surveys. Eight patients
(26.7%) in Arm A died within the first twelve weeks fol-
lowing RT, additional 4 patients (13.3%) died within
6 months due to tumor progression. In Arm B, 9 pa-
tients died (30.0%) within 3 months, and 3 furtherTable 2 Results of OMED, VAS, and neuropathic pain
Intervention group (n = 30)
OMED n Mean SD
Baseline (t0) 30 56.8 132.2
RT completed (t1) 30 43.8 88.7
After 3 months (t2) 22 30.2 59.1
After 6 months (t3) 18 20.8 46.9
Visual analog scale
Baseline (t0) 30 48.2 20.5
RT completed (t1) 30 23.8 20.2
After 3 months (t2) 22 15.8 12.1
After 6 months (t3) 18 16.7 14.8
Neuropathic pain
Baseline (t0) 30 0.2 0.4
RT completed (t1) 30 0.1 0.3
After 3 months (t2) 22 0.2 0.4
After 6 months (t3) 18 0.2 0.4
VAS was measured from 0 to 100 with 0 indicating no pain at all and 100 indicating
Abbreviations: SD standard deviation, OMED oral morphine equivalent dose, VAS vispatients (10.0%) within 6 months. Mortality did not dif-
fer between groups.
In arm A, NSAR were taken by 63.3% (n = 19) and
opioid analgetics by 36.7% (n = 11) of the patients. In
arm B, 76.7% (n = 23) of the patients took NSAR and
43.3% (n = 13) opioids. During the resistance training in
arm A 30% (n = 9) of the patients reported resting pain
and 46.7% (n = 14) pain upon movement; four of these
patients (13.3%) were forced to take relief medication.
The course of VAS in the intervention group was sig-
nificantly lower both during and after RT (AUC, p < .001)
(Figure 2a, 2b). The taking of relief medication showed
the same result, with significantly fewer analgetics being
necessary both during and after RT in arm A (p < .001)
(Table 2).
In the course of time, the OMED decreased in arm A,
but increased in arm B. After three months a positive
trend in favor of arm A was discernible, and after six
months the OMED was significantly lower (p = .018)
(Figure 3a). At end of RT the mean VAS values showed
a response to therapy in both groups, albeit significantly
lower in arm A after three and six months (p < .001)
(Table 3). In arm B the pain symptoms worsened up to
six months after RT, while in the intervention group the
VAS values remained virtually constant (Figure 3b). It
was not possible to discern any difference between the
groups in terms of neuropathic pain.
In Arm A, complete response and partial response rates
at 12 weeks were documented in 4.6% and 63.6%, there-
fore 68.2% were responders (p = .172). After 6 months,
72.2% of patients were responders. Patients of control
group showed a complete response and partial response atControl group (n = 30)
n Mean SD p-value
30 45.0 86.2 0.841
30 50.7 88.7 0.452
21 62.7 84.6 0.091
18 76.7 103.6 0.018
30 51.3 26.9 0.393
30 33.3 24.6 0.118
21 40.7 21.7 <0.001
18 50.3 22.8 <0.001
30 0.2 0.4 0.749
30 0.2 0.4 0.326
21 0.2 0.4 0.619
18 0.2 0.4 0.694
worst possible pain.
ual analog scale.






























Figure 3 OMED and VAS of both groups at measured points. a. OMED of both groups at measured points (T0, T1, T2, T3). b. VAS of both
groups at measured points (T0, T1, T2, T3).
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The rate after 6 months was only 22.2% (Table 4).
Discussion
The vertebral column is the main localization of bone me-
tastases and pain is the most frequently reported symptom
of an advanced stage of a tumor disease. Palliative RT is
an effective means for the treatment of pain in patients
with bone metastases of the spinal column [7,14] and will
continue to remain the principal option for the treatment
of painful bone metastases [15], with analgetics, systemic
therapy, bisphosphonates, and minimal invasive surgeryalso playing their respective roles [7]. A non-pharmaco-
logical adjunctive therapy in the form of isometric training
exercises of the autochthonous muscles has not yet been
investigated and formed the basic concept of this novel
pilot study.
Many other previously conducted studies have fre-
quently used the pain response as the endpoint and pre-
sented this in the results. In most cases, a detailed
report on the change in analgetics in the course of time
was a weak point in the study design. The inclusion of
the concomitant medication makes it possible to more
exactly comprehend the therapeutic pain response to
Table 3 Results of VAS, and concomitant medication during RT (day 1–10) and 12 weeks follow up
Intervention group (n = 30) Control group (n = 30)
Day 1–10 during RT n Mean SD n Mean SD p-value
VAS 30 192.5 126.9 30 394.4 223.0 <.001
CM 30 0.9 2.1 30 14.1 8.3 <.001
Week 1–12 after RT
VAS 30 214.2 141.2 30 406.3 222.3 <.001
CM 30 2.7 4.5 30 17.7 10.3 <.001
Abbreviations: VAS visual analog scale, CM concomitant medication.
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reduction during RT in the intervention group, whereas
in arm B the pain symptoms increased again until six
months after RT. Analgesic medication, measured by
OMED, remained constant up to the end of RT in both
groups; in arm A the requirement for analgetic medica-
tion decreased until up to six months after RT, while it
significantly increased again in arm B (p = .018). Also the
requirement for pain medication in arm A was signifi-
cantly lower both during and after RT (p < .001).
Previous clinical studies have shown that tumor pa-
tients can indeed profit from physical training measures
during and following medical treatment [4,16,17]. A
Norwegian study of 355 patients were the RT-related
pain response rates significantly lower after 2 months,
but the OMED increases from 40 to 60 mg (p < .001)
[18]. This increase in OMED could also be seen in our
control group.
Patients affected by this condition are usually immobi-
lized, primarily due to the risk of pathological fractures
and the related danger of spinal cord compression. In
our study we were able to demonstrate the positive effectTable 4 Results of pain response
Intervention group Control group
After 12 weeks n % n % p-value
CR 1 4.6 3 14.3 0.196
PR 14 63.6 7 33.3
PP 2 9.1 5 23.8
SP 5 22.7 6 28.6
Responders 15 68.2 10 47.6 0.172
Non-responders 7 31.8 11 52.4
After 6 months
CR 4 22.2 3 16.7 0.049
PR 12 66.8 3 16.7
PP 1 5.5 4 22.2
SP 1 5.5 8 44.4
Responders 13 72.2 4 22.2 0.014
Non-responders 5 27.8 14 77.8
Abbreviations: CR complete response, PR partial response, PP pain progression,
SP stable pain.of a training regimen to strengthen the muscles of the
back as an adjunct to RT in reducing pain. Optimal treat-
ment of skeletal metastases is complex, and a multidis-
ciplinary approach is often needed. Analgetics should be
administered in order to control symptoms additional to
palliative RT. Some patients with bone metastases mani-
fest bone pain with distinguishable neuropathic features
[19]. It was not possible to demonstrate a difference bet-
ween the two groups regarding neuropathic pain compo-
nents. Single and multiple fractionated RT doses were
equally effective in the palliative treatment of pain and the
functional impact on extra- and intraspinal localizations
[20], which is why the fractionating is not specified in the
protocol. In the literature, the response to therapy has so
far generally been expressed on the basis of pain [21]. In
their study in 160 patients, Foro et al. showed a complete
and partial response in the 30 Gy arm in 13% and 73% of
the cases, respectively [13].
Chow et al. showed in their prospectively collected
group of 518 patients the complete, partial, and overall re-
sponse rates ranged from 21% to 25%, 26% to 30%, and
46% to 50% [22]. These results correlate with our control
group after three months. In another work, Chow et al.
showed in a systematic review of 25 randomized con-
trolled trials complete response rates of 23% in the single
fraction arm and 24% in the multiple fraction arm [23].
Our study presented complete response rates in the inter-
vention group after three and six months of 4.6% and
22.2%, respectively, versus rates of 14.3% and 16.7%, re-
spectively, in the control group; these were lower in both
arms, although after six months a considerable 72.2% ver-
sus 22.2% of the patients were responders.
The effects of resistance training became apparent and
significant in reduced pain after six months, which sug-
gests a higher benefit for survivors.
Because all patients are in advanced stages of their
cancer, 40% of the patients in either group were lost to
follow-up due to progressive disease and subsequent
death. Further limitations of the study are the relatively
small sample size, the variety of primary tumors and pa-
tient conditions, and the exclusion of patients presenting
with cervical spine metastases. For feasibility reasons,
patients’ compliance with the training program in their
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pleted documentation forms.
Among the strengths of the study are its randomized
design and a relatively low drop-out rate, as well as
standardized and specific measures to assess pain re-
sponse among patients with bone metastases. This is, to
our knowledge, the very first application of a resistance
exercise program in patients with spinal metastases inte-
grated in routine RT, to enhance their functional capacity
and mobility, to reduce pain from spinal metastases.
Conclusion
In this group of patients we were able to show that guided
isometric resistance training of the autochthonous mus-
cles can improve pain relief over a 6-months period in pa-
tients with stable spinal metastases. Importantly, the
intervention was able to reduce OMED as well as con-
comitant pain medication. This exercise is a promising
and effective therapeutic approach to reduce pain to pa-
tients suffering from spinal metastases. Large controlled
trials are necessary to confirm these findings.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HR and JD developed and planned this trial. TB is responsible for statistical
considerations/basis of the analysis. GO, MA, and TW estimated the stability
of bone metastases. HR, MK, SR, MH, and IS performed the examinations and
RT supervisions. HR and AG made the data collection. HR performed the
physical exercise. All authors read and approved the final manuscript.
Acknowledgements
The authors thank all of the study participants for their great effort. We
acknowledge financial support by Deutsche Forschungsgemeinschaft and
Ruprecht-Karls-Universität Heidelberg within the funding program Open
Access Publishing.
Author details
1Department of Radiation Oncology, University Hospital of Heidelberg, Im
Neuenheimer Feld 400, Heidelberg 69120, Germany. 2Department of Medical
Biometry, University Hospital of Heidelberg, Im Neuenheimer Feld 305,
Heidelberg 69120, Germany. 3Department of Orthopaedics and Trauma
Surgery, University Hospital of Heidelberg, Schlierbacherstrasse 120a,
Heidelberg 69118, Germany.
Received: 25 February 2014 Accepted: 30 June 2014
Published: 5 July 2014
References
1. Coleman RE: Metastatic bone disease: Clinical features, pathophysiology
and treatment strategies. Cancer Treat Rev 2001, 27:165–176.
2. Harrington KD: Orthopedic surgical management of skeletal
complications of malignancy. Cancer 1997, 80(8):1614–1627.
3. Janjan N, Lutz ST, Bedwinek JM, Hartsell WF, Ng A, Pieters RS Jr,
Ratanatharathorn V, Silberstein EB, Taub RJ, Yasko AW, Rettenmaier A:
Therapeutic guidelines for the treatment of bone metastasis: a report
from the American College of Radiology Appropriateness Criteria Expert
Panel on Radiation Oncology. J Palliat Med 2009, 12:417–426.
4. Hayes S, Spence R, Galvao D, Newton RU: Australian association for
exercise and sport science potion stand: optimising cancer outcomes
through exercise. J Sci Med Sport 2009, 12:428–434.
5. Mitera G, Probyn L, Ford M, Donovan A, Rubenstein J, Finkelstein J,
Christakis M, Zhang L, Campos S, Culleton S, Nguyen J, Sahgal A, Barnes E,
Tsao M, Danjoux C, Holden L, Yee A, Khan L, Chow E: Correlation ofcomputed tomography imaging features with pain response in patients
with spine metastases after radiation therapy. Int. J Radiation Oncol Biol
Phys 2011, 81(3):827–830.
6. Wu JSY, Monk G, Clark T, Robinson J, Eigl BJ, Hagen N: Palliative
radiotherapy improves pain and reduces functional interference in
patients with painful bone metastases: a quality assurance study. Clin
Oncol (R Coll Radiol) 2006, 18:539–544.
7. Chow E, Harris K, Fan G, Tsao M, Sze WM: Palliative radiotherapy trials for
bone metastases: A systemic review. J Clin Oncol 2007, 25:1423–1436.
8. Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G: Physical
exercise in cancer patients during and after medical treatment: A
systemic review of randomized and controlled clinical trials. J Clin Oncol
2005, 23:3830–3842.
9. Galvao DA, Newton RU: Review of exercise intervention studies in cancer
patients. J Clin Oncol 2005, 23:899–909.
10. Karnofsky DA, Burchenal JH: The Clinical Evaluation of Chemotherapeutic
Agents in Cancer. In Evaluation of Chemotherapeutic Agents. Edited by
MacLeod CM. New York: Columbia Univ Press; 1949:191–205.
11. Rief H, Jensen AD, Bruckner T, Herfarth K, Debus J: Isometric muscle
training of the spine musculature in patients with spinal bony
metastases under radiation therapy. BMC Cancer 2011, 11:482.
12. Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, Hahn C, van der Linden Y,
Hartsell W, Kumar E: Update of the international concensus on palliative
radiotherapy endpoints for future clinical trials in bone metastases. Int J
Radiation Oncol Biol Phys 2012, 82(5):1730–7.
13. Foro Arnalot P, Fontanals AV, Galcerán JC, Lynd F, Latiesas XS, de Dios NR,
Castillejo AR, Bassols ML, Galán JL, Conejo IM, López MA: Randomized
clinical trial with two palliative radiotherapy regimens in painful bone
metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction.
Radiother Oncol 2008, 89(2):150–5.
14. Klimo P Jr, Kestle JR, Schmidt MH: Clinical trials and evidence-based medicine
for metastatic spine disease. Neurosurg Clin N Am 2004, 15:549–564.
15. Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, Howell D, Konski A,
Kachnic L, Lo S, Sahgal A, Silverman L, von Gunten C, Mendel E, Vassil A,
Bruner DW, Hartsell W: Palliative radiotherapy for bone metastases: An
ASTRO evidence-based guideline. Int J Radiation Oncol Biol Phys 2011,
79(4):965–976.
16. Maddocks M, Mockett S, Wilcock A: Is exercise an acceptable and practical
therapy for people with or cured of cancer? A systemic review. Cancer
Treat Rev 2009, 35(4):383–90.
17. Stevinson C, Fox KR: Feasibility of an exercise rehabilitation programme
for cancer patients. Eur J Cancer Care 2006, 15:386–396.
18. Zaikova O, Fossa SD, Kongsgaard U, Kvaløy S, Giercksky KE, Skjeldal S: Pain
after palliative radiotherapy for spinal metastases. Clin Oncol (R Coll
Radiol) 2010, 22(10):828–36.
19. Kerba M, Wu JSY, Duan Q, Hagen NA, Bennett MI: Neuropathic pain
features in patients with bone metastases referred for palliative
radiotherapy. J Clin Oncol 2010, 28:4892–4897.
20. Zeng L, Chow E, Zhang L, Culleton S, Holden L, Jon F, Khan L, Tsao M,
Barnes E, Danjoux C, Sahgal A: Comparison of pain response and
functional interference outcomes between spinal and non-spinal bone
metastases treated with palliative radiotherapy. Support Care Cancer 2012,
20(3):633–9.
21. Nguyen J, Chow E, Zeng L, Zhang L, Culleton S, Holden L, Mitera G, Tsao M,
Barnes E, Danjoux C, Sahgal A: Palliative response and functional
interference outcomes using the Brief Pain Inventory for spinal bony
metastases treated with conventional radiotherapy. Clin Oncol (R Coll
Radiol) 2011, 23(7):485–91.
22. Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH: International
concensus on palliative radiotherapy endpoints for future clinicla trials
in bone metastases. Radiother Oncol 2002, 64(3):275–280.
23. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S: Update on the
systematic review of palliative radiotherapy trials for bone metastases.
Clin Oncol (R Coll Radiol) 2012, 24(2):112–124.
doi:10.1186/1471-2407-14-485
Cite this article as: Rief et al.: Pain response of resistance training of
the paravertebral musculature under radiotherapy in patients with
spinal bone metastases – a randomized trial. BMC Cancer
2014 14:485.
